Impact of Apalutamide on Prostate Cancer Outcomes

Created using ChatSlide

{"description":"This presentation will delve into the recent phase 3, double-blind trial evaluating the efficacy and safety of apalutamide in a sample of 2109 participants, as reported in the NEJM on May 31, 2026. The trial demonstrated improved metastasis-free survival and increased adverse events in the apalutamide group. We will discuss the benefits and challenges of ADT with apalutamide, including detailed safety and mortality findings. The session will conclude with insights on safety...